Cell Pathways drops on Aptosyn non-approval

CLPA was off $20.688 (69 percent) to $9.313 on Monday following Friday's announcement after the market close that its NDA for Aptosyn exisulind to treat familial adenomatous polyposis (FAP) is non-app...